This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
by Zacks Equity Research
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
by Zacks Equity Research
If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates
by Zacks Equity Research
CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024.
FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief
by Zacks Equity Research
Pacira receives FDA approval for a new iovera Smart Tip aimed at expanding pain management capabilities to deeper nerves like the medial branch nerve.
Here's Why You Should Consider Buying Atara Biotherapeutics Stock
by Zacks Equity Research
Here, we discuss some reasons why buying ATRA stock now may turn out to be a prudent move.
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal
by Zacks Equity Research
Hoth stock soars as a mid-stage study meets the goal, showing significant improvement in skin toxicities related to EFGR inhibitor therapy in all HT-001-treated patients.
Geron Stock Rallies More Than 60% in a Year: Here's Why
by Zacks Equity Research
FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
by Zacks Equity Research
EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.
AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs
by Zacks Equity Research
ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
by Zacks Equity Research
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
by Zacks Equity Research
The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
by Zacks Equity Research
Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
by Zacks Equity Research
Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.
Neumora Stock Hits Record Low on Depression Drug Study Failure
by Zacks Equity Research
NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
by Zacks Equity Research
The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
by Zacks Equity Research
Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
by Zacks Equity Research
The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723
by Zacks Equity Research
Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer
by Zacks Equity Research
The European Commission approves Bristol Myers' Opdivo plus Yervoy for first-line treatment of MSI-H or dMMR unresectable or metastatic colorectal cancer.
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?
by Zacks Equity Research
2024 was a transformational year for MNMD as it executed many important milestones.
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
by Zacks Equity Research
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.
AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC
by Zacks Equity Research
AstraZeneca wins approval in the EU for the label expansion of Tagrisso to treat adult patients with locally advanced, unresectable NSCLC.
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
by Nalak Das
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.